Monday, 3 April 2017

Revitalize Your Heart With Cardiac Resynchronization Therapy

Heart-related diseases have become extremely common due to the hectic lifestyle led by people. Some people are diagnosed with arrhythmia, an irregular heartbeat that can prove fatal. More than 2 million people in the U.S. reportedly suffer from Atrial Fibrillation (AF), a type of arrhythmia, and the geriatric populace is highly susceptible to the same. 


Cardiac Resynchronization Therapy (CRT) is a device designed to treat heart failure. It sends electrical impulses to the lower chambers of heart, which facilitates synchronized heart beats. CRT-P (CRT-pacemaker) and CRT-D (CRT-defibrillator) are two types of implantable cardioverter defibrillators (ICDs) that aid in treating heart failure. A CRT-D device can treat arrhythmia by delivering shock to the heart, while a CRT-P device does the same when it beats at an abnormally slow rate.

Novel Developments

EBR Systems, Inc., an American manufacturer of cardiac implants, has received U.S. FDA approval for the “Wireless Stimulation Endocardially” (WiSE) technology to reduce the dependency on lead pacemakers to treat heart failure. It boasts of being the world’s only wireless pacemaker that stimulates the endocardium of the left ventricle. It has been reported that a significant percentage of consumers responded positively to this therapy. WiSE is expected to benefit nearly 1.5 million patients globally.

In 2016, Medtronic Plc received approval from U.S. FDA for its proprietary product “Claria MRI Quad Cardiac Resynchronization Therapy Defibrillator (CRT-D) SureScan.” Medtronic’s EffectivCRT Diagnostic, which automatically estimates the strength of each left ventricular pace, is a component of Claria. Claria automatically adjusts pacing rates during AF, without adversely impacting the average heart rate. This device is designed to run in 1.5 and 3 Tesla Magnetic Resonance Imaging (MRI) machines.

Market Outlook

The global cardiac resynchronization therapy (CRT) market is anticipated to reach USD 8 billion by 2025. The rising cases of heart failure worldwide are expected to spur market demand from 2014 to 2025 (forecast period).

The Sudden Cardiac Arrest Foundation has estimated that nearly 6 million suffer from cardiac disorders. This is anticipated to spur market growth in order to minimize hospital costs. CRT-D devices are anticipated to dominate the market over the forecast period.

North America accounted for over 30% of the market share in 2015 due to the growing regional geriatric population. Latin America and Asia Pacific are expected to contribute over 30% to global revenue by 2025. Some of the prominent market players are Boston Scientific Corporation, LivaNova Plc., and Medtronic Plc. 

In-depth report on global cardiac resynchronization therapy (CRT) market by Grand View Research:


No comments:

Post a Comment